Vertex Pharmaceuticals reports positive data

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) reported positive results from two Phase 3 studies of the tezacaftor (VX-661)/ivacaftor combination treatment for cystic fibrosis sending the stock price soaring $18.34 to close at $108.01.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 

Business

Complete coverage of business news in the Twin Cities, Minnesota and elsewhere, including Fortune 500 Minnesota companies: UnitedHealth Group, Target, Best Buy, 3M, CHS, U.S. Bancorp, General Mills, C.H. Robinson, Land O’Lakes, Ecolab, Ameriprise Financial, Xcel Energy, Hormel Foods, Thrivent Financial, Polaris, Securian Financial Group, Fastenal and Patterson Cos.